Taken together, administration of a BRAF/MEK inhibitor not only increases RAI delivery to target lesions but also may contribute to increasing radiosensitivity to augment 131I therapeutic efficacy in thyroid cancer carrying RAS or BRAF mutations. This evidence concerns the gene BRAF and thyroid gland carcinoma.